IGC Pharma, Inc.（IGC）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

2026年7月10日

32/ 100

GoAI 評分

賣出

估值

22

偏貴

情緒

53

多空交錯

風險

50

風險偏高

動能

29

動能減弱

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

公司概況

公司網站

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Ram Mukunda
上市以來: 2006年5月24日
僱員: 70

市場位置

日內區間

目前US$0.2624

US$0.2624US$0.271

52週區間

目前US$0.2624

US$0.235US$0.4508

開盤價: US$0.2696
前收盤價: US$0.276
成交量: 12.15萬; 0.18× 平均值
平均成交量: 66.26萬; 日均成交量
市值: 2625.89萬 USD
貝塔: 0.48; 市場參考 1
50天平均值: US$0.2824; 低於平均水平-7.10%
200天平均值: US$0.2839; 低於平均水平-7.57%

財務數據

財務快照

估值與收益率

企業價值: 2571.4萬 USD
EV/EBITDA: -3.96×
盈餘收益率: -26.20%
自由現金流收益率: -24.43%

獲利能力和效率

股東權益報酬率: -106.98%
資產報酬率: -71.29%
投入資本報酬率: -144.79%

財務健康

流動比率: 0.4×
奧特曼 Z 分數: -17.09
皮奧特羅斯基 F 分數: 1 共 9 個

財務報表

利潤率趨勢

獲利能力占已公布營收的百分比。

毛利率營業利益率淨利潤率

損益趨勢

營收

118.6萬 USD-6.69%

營業利益

−1020.3萬 USD-37.03%

淨利

−654.8萬 USD+8.05%

財務報表: 損益表
項目（USD）	2026會計年度	2025會計年度	2024會計年度	2023會計年度	2022會計年度
營收	118.6萬 USD	127.1萬 USD	134.5萬 USD	91.1萬 USD	39.7萬 USD
銷貨成本	83.4萬 USD	65.2萬 USD	61.2萬 USD	106.9萬 USD	20.3萬 USD
毛利	35.2萬 USD	61.9萬 USD	73.3萬 USD	−15.8萬 USD	19.4萬 USD
研究與開發	519.3萬 USD	365.5萬 USD	377.3萬 USD	346.1萬 USD	233萬 USD
銷售、一般及管理費用	536.2萬 USD	441萬 USD	675.8萬 USD	795.2萬 USD	1329.2萬 USD
營業費用	1055.5萬 USD	806.5萬 USD	1053.1萬 USD	1141.3萬 USD	1562.2萬 USD
折舊和攤銷	5.8萬 USD	61.8萬 USD	63.7萬 USD	65.7萬 USD	65.1萬 USD
營業利益	−1020.3萬 USD	−744.6萬 USD	−979.8萬 USD	−1157.1萬 USD	−1542.8萬 USD
淨利	−654.8萬 USD	−712.1萬 USD	−1300萬 USD	−1150.6萬 USD	−1501.6萬 USD

公司資料更新於 2026年10月13日。

財報歷史與展望

最新財年每股收益: -0.072; 2026會計年度
最新財年收入: 118.6萬 USD; 2026會計年度 · 年增-6.69%

年度每股收益趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

年度營收趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

IGC 訊息

accessnewswire.com2026年10月13日

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

POTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial…

閱讀原始碼

defenseworld.net2026年10月3日

IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%

IGC Pharma, Inc. (NYSEAMERICAN:IGC - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,072,899 shares, an…

閱讀原始碼

accessnewswire.com2026年9月28日

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1,…

閱讀原始碼

accessnewswire.com2026年8月17日

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage…

閱讀原始碼

accessnewswire.com2026年8月11日

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that…

閱讀原始碼

accessnewswire.com2026年7月29日

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that…

閱讀原始碼

IGC同業公司

NHC

National HealthCare Corporation

US$228.7

-0.51%

CATX

Perspective Therapeutics, Inc.

US$2.4188

-4.02%

INFU

InfuSystem Holdings, Inc.

US$13.735

+0.99%

LCTX

Lineage Cell Therapeutics, Inc.

US$0.9646

+1.10%

ELMD

Electromed, Inc.

US$28.01

-0.36%

PLX

Protalix BioTherapeutics, Inc.

US$2.765

-0.54%

持有IGC的ETF

報告持有此股票曝險的交易所交易基金。

ETF市場價值重量AUM費用率價格 / 1日

Vanguard Extended Market ETFVXF24.38萬0.00%954億 USD0.05%US$233.15-0.16%

AdvisorShares Psychedelics ETFPSIL24.09萬0.53%4574.2萬 USD1.84%US$20.765-2.28%

Vanguard Extended Market ETFVXF

市場價值: 24.38萬
重量: 0.00%
AUM: 954億 USD
費用率: 0.05%
價格 / 1日: US$233.15-0.16%

AdvisorShares Psychedelics ETFPSIL

市場價值: 24.09萬
重量: 0.53%
AUM: 4574.2萬 USD
費用率: 1.84%
價格 / 1日: US$20.765-2.28%

IGC Pharma, Inc.

IGC公司概覽

公司概況

IGC Pharma, Inc.

IGC公司概覽

GoAI 研究快照

公司概況

市場位置

財務數據

財務快照

估值與收益率

獲利能力和效率

財務健康

財務報表

利潤率趨勢

損益趨勢

財報歷史與展望

年度每股收益趨勢

年度營收趨勢

IGC 訊息

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC同業公司

持有IGC的ETF

繼續GoAI的研究

IGC公司概覽

公司概況

市場位置

IGC公司概覽

公司概況

IGC公司概覽

公司概況

市場位置

IGC公司概覽

GoAI 研究快照

公司概況

市場位置

財務數據

財務快照

估值與收益率

獲利能力和效率

財務健康

財務報表

利潤率趨勢

損益趨勢

財報歷史與展望

年度每股收益趨勢

年度營收趨勢

IGC 訊息

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC同業公司

持有IGC的ETF

繼續GoAI的研究